Ilex Clolar Gets Cmte. Nod On Accelerated Approval For ALL, But Not AML
This article was originally published in The Pink Sheet Daily
Executive Summary
Committee concludes that unconfirmed response can be considered useful for evaluating the drug’s effectiveness. FDA’s Pazdur voices concern to committee that Ilex may not have shown “due diligence” in initiating confirmatory trials.